Cross Cultural Adaptation of International Physical Activity Questionaire Short Form in Urdu Version

July 17, 2021 updated by: Riphah International University
The IPAQ-SF scale is widely used in our clinical settings. The translated version of IPAQ-SF scale in Urdu will help the clinician in collecting data thus, easy to understand for the patient and making it more desirable in our region.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The purpose of study is to translate IPAQ-SF (International Physical Activity Questionnaire- short form) scale in Urdu and to determine the validity & reliability of IPAQ-SF in Urdu version. Patients who are at high risk of chronic diseases such as cardiovascular disease, diabetes, and hypertension age between 30 to 65 years and can understand Urdu and English language are included in my study. 6mint walk test performed to assess aerobic capacity and endurance and physical activity over the last seven days is recorded on the translated version of IPAQ-SF in Urdu and then back of Urdu into English.

Study Type

Observational

Enrollment (Actual)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Punjab
      • Rawalpindi, Punjab, Pakistan, 43600
        • Pakistan Railway General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Diseased and Healthy individual group to evaluate the Physical Activity and do validation of IPAQ Short form Urdu Version. Test retest reliability in both group for IPQ short form urdu version.

Description

Inclusion Criteria:

  • Patients who have chronic diseases, such as cardiovascular, pulmonary and metabolic disease will consider as high risk, those who have more than two number of CAD risk factor will categorize as mild and patients have less than two risk factor of CAD will consider as low risk factor.(ACSM risk stratification guide lines)

Those who can read and understand English and Urdu as well.

Exclusion Criteria:

  • Those with known Parkinson's disease, cerebrovascular disease or dementia.

Individuals have difficulty with reading because of low educational level

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Disease Population
50 Patients who have chronic diseases, such as cardiovascular, will consider as high risk, those who have more than two number of CAD risk factor will categorize as mild and patients have less than two risk factor of CAD will consider as low risk factor. (ACSM risk stratification guide lines)
Other: Validation & reliability
Translated version of IPAQ(SF) validation & Reliability
Other Names:
  • Translated Tool
Healthy
30 Healthy individual with no cardiac diseased.
Other: Validation & reliability
Translated version of IPAQ(SF) validation & Reliability
Other Names:
  • Translated Tool

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate Pressure Product
Time Frame: One day
Rate pressure product is amount of stress on cardiac muscle during each beat and amount of blood pressure exert against arterial circulation (SBP).
One day
6 minute Walk Test
Time Frame: One day
Area that is covered during six minutes shows the result with whom functional capability is compared. Walkway with no obstruction and an area of thirty meter is used and patient is told to keep walking for the duration of six minutes.
One day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Riphah International University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 21, 2020

Primary Completion (Actual)

April 30, 2021

Study Completion (Actual)

April 30, 2021

Study Registration Dates

First Submitted

July 17, 2021

First Submitted That Met QC Criteria

July 17, 2021

First Posted (Actual)

July 22, 2021

Study Record Updates

Last Update Posted (Actual)

July 22, 2021

Last Update Submitted That Met QC Criteria

July 17, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • REC00758 Syeda Sumaira

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe